Tom Lynch out­lines his come­back strat­e­gy for Bris­tol-My­ers’ bad­ly bruised R&D or­ga­ni­za­tion

When Tom Lynch took the top R&D job at Bris­tol-My­ers Squibb, he got one of the best — and at the same time, one of the hard­est — jobs in biotech.

It was one of the best be­cause Bris­tol-My­ers built what is wide­ly con­sid­ered one of the most in­no­v­a­tive re­search groups for a bio­phar­ma of its size, in a heavy­weight class not known for home­made break­throughs. It was one of the hard­est be­cause the group had just de­railed, giv­ing up its first-place po­si­tion in im­muno-on­col­o­gy in a hard fall on a mis­guid­ed late-stage ef­fort on lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.